ReviewEuropean journal of epidemiology2018
Will biomarker-based diagnosis of Alzheimer's disease maximize scientific progress? Evaluating proposed diagnostic criteria.
Review in European journal of epidemiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cross-sectional associations of amyloid burden with semantic cognition in older adults without dementia: A systematic review and meta-analysis.Mechanisms of ageing and development · 2020Pooled it
- Time to align sensitive cognitive assessment with protein biomarkers in Alzheimer's disease.Journal of neuropsychology · 2025Article
- Changing definitions of disease: Transformations in the diagnostic criteria for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Rethinking neuropsychological test validity in dementia assessment: a critical review in the age of neuroimaging and digital markers.Frontiers in human neuroscience · 2025Review
- The heritability of blood-based biomarkers related to risk of Alzheimer's disease in a population-based sample of early old-age men.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Accelerated hypometabolism with disease progression associated with faster cognitive decline among amyloid positive patients.Frontiers in neuroscience · 2023Article
- Developments in scalable strategies for detecting early markers of cognitive decline.Translational psychiatry · 2022Review
- Capturing Cognitive Aging in Vivo: Application of a Neuropsychological Framework for Emerging Digital Tools.JMIR aging · 2022Article
- Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Review
- Aduhelm, the Newly Approved Medication for Alzheimer Disease: What Epidemiologists Can Learn and What Epidemiology Can Offer.American journal of epidemiology · 2022Article
- Theoretical impact of the AT(N) framework on dementia using a community autopsy sample.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021Article
- Biopsychosocial pathways in dementia inequalities: Introduction to the Michigan Cognitive Aging Project.The American psychologist · 2021Article
- A Workshop on Cognitive Aging and Impairment in the 9/11-Exposed Population.International journal of environmental research and public health · 2021Review
- Application of neuropsychological criteria to classify mild cognitive impairment in the active study.Neuropsychology · 2020Article
- Education and Cognitive Functioning Across the Life Span.Psychological science in the public interest : a journal of the American Psychological Society · 2020Review
- Trends in the public health significance, definitions of disease, and implications for prevention of Alzheimer's disease.Current epidemiology reports · 2020Article
- Objectives, design and main findings until 2020 from the Rotterdam Study.European journal of epidemiology · 2020Article
- Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls.Journal of Alzheimer's disease : JAD · 2020Article
- Semantic loss marks early Alzheimer's disease-related neurodegeneration in older adults without dementia.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
- Expanding disease and undermining the ethos of medicine.European journal of epidemiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A recently published framework for the diagnosis of Alzheimer's disease (AD) in research studies would allow diagnosis on the sole basis of two biomarkers (β-amyloid and pathologic tau), even in people with no objective or subjective memory or cognitive changes. This revision will have substantial implications for future Alzheimer's research, and the changes should be rigorously evaluated before widespread adoption. We propose three principles for evaluating any revision to diagnostic frameworks for AD: (1) does the revision improve the validity of the diagnosis; (2) does the revision improve the reliability or reduce the expense of the diagnosis; and (3) will the revision foster innovative and rigorous research across populations. The new diagnostic framework is unlikely to achieve any of these goals. Instead, it has the potential to handicap future researchers, and slow progress towards identifying effective strategies to prevent or treat AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.